Free Trial

Finch Therapeutics Group (FNCH) Competitors

Finch Therapeutics Group logo
$12.50 0.00 (0.00%)
As of 01:37 PM Eastern

FNCH vs. FBRX, ENTX, TCRX, IGMS, VRCA, CABA, EPIX, ZURA, IPA, and QNCX

Should you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Forte Biosciences (FBRX), Entera Bio (ENTX), TScan Therapeutics (TCRX), IGM Biosciences (IGMS), Verrica Pharmaceuticals (VRCA), Cabaletta Bio (CABA), ESSA Pharma (EPIX), Zura Bio (ZURA), ImmunoPrecise Antibodies (IPA), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry.

Finch Therapeutics Group vs. Its Competitors

Forte Biosciences (NASDAQ:FBRX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Forte Biosciences presently has a consensus target price of $61.00, indicating a potential upside of 499.21%. Given Forte Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Forte Biosciences is more favorable than Finch Therapeutics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forte Biosciences
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Forte Biosciences has a beta of 2.97, indicating that its share price is 197% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Forte BiosciencesN/AN/A-$35.48M-$16.29-0.62
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.42

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 5.9% of Forte Biosciences shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Finch Therapeutics Group had 1 more articles in the media than Forte Biosciences. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Forte Biosciences. Forte Biosciences' average media sentiment score of 1.29 beat Finch Therapeutics Group's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Forte Biosciences Positive
Finch Therapeutics Group Neutral

Finch Therapeutics Group's return on equity of -69.14% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Forte BiosciencesN/A -149.15% -114.25%
Finch Therapeutics Group N/A -69.14%-26.92%

Summary

Forte Biosciences beats Finch Therapeutics Group on 7 of the 12 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNCH vs. The Competition

MetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$20.08M$271.25M$5.52B$9.41B
Dividend YieldN/AN/A3.80%4.04%
P/E Ratio-1.42N/A28.0419.84
Price / SalesN/A430.80429.5399.59
Price / CashN/A22.4435.8457.94
Price / Book0.889.998.125.65
Net Income-$74.75M-$110.10M$3.25B$258.00M
7 Day Performance-1.96%-0.17%0.97%2.09%
1 Month Performance-6.94%15.77%7.36%11.13%
1 Year Performance706.45%20.13%31.31%18.40%

Finch Therapeutics Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
0.7891 of 5 stars
$12.50
flat
N/A+756.2%$20.08MN/A-1.42190
FBRX
Forte Biosciences
3.3927 of 5 stars
$12.48
-1.3%
$61.00
+388.8%
+42,831.0%$83.28MN/A-0.775Gap Down
ENTX
Entera Bio
2.9448 of 5 stars
$1.78
-2.7%
$10.00
+461.8%
+7.9%$83.18M$180K-6.8520
TCRX
TScan Therapeutics
3.5939 of 5 stars
$1.70
+17.2%
$7.80
+358.8%
-74.3%$82.06M$2.82M-1.56100Gap Up
IGMS
IGM Biosciences
4.6078 of 5 stars
$1.33
-1.5%
$5.50
+313.5%
-89.3%$80.70M$2.68M-0.41190Positive News
VRCA
Verrica Pharmaceuticals
4.4022 of 5 stars
$0.86
+3.8%
$8.00
+828.2%
-89.2%$76.77M$7.57M-0.7240
CABA
Cabaletta Bio
2.833 of 5 stars
$1.51
+1.3%
$14.43
+855.5%
-77.8%$75.61MN/A-0.5950
EPIX
ESSA Pharma
1.0211 of 5 stars
$1.71
+0.6%
$2.00
+17.0%
-67.2%$75.46MN/A-2.7150
ZURA
Zura Bio
3.0461 of 5 stars
$1.20
+9.1%
$14.33
+1,094.4%
-44.0%$75.21MN/A-1.713News Coverage
Gap Up
IPA
ImmunoPrecise Antibodies
3.0443 of 5 stars
$1.76
+8.0%
$4.00
+127.3%
+93.3%$74.60M$18.16M-1.5280Gap Up
QNCX
Quince Therapeutics
3.1351 of 5 stars
$1.61
-1.2%
$8.00
+396.9%
+140.1%$74.11MN/A-1.1660News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:FNCH) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners